Johnson & Johnson COVID-19 vaccine

GPTKB entity

Statements (41)
Predicate Object
gptkbp:instanceOf vaccine
gptkbp:age 18 years and older
gptkbp:alsoKnownAs gptkb:Janssen_COVID-19_vaccine
gptkbp:approvedBy gptkb:Canada
gptkb:European_Union
gptkb:South_Africa
gptkb:World_Health_Organization
gptkbp:boosterInterval 2 months after initial dose
gptkbp:boosterRecommended yes
gptkbp:clinicalTrialPhase gptkb:ENSEMBLE
gptkbp:contains recombinant, replication-incompetent adenovirus type 26 expressing the SARS-CoV-2 spike protein
gptkbp:countryOfOrigin gptkb:United_States
gptkbp:developer gptkb:Johnson_&_Johnson
gptkb:Janssen_Pharmaceuticals
gptkbp:dosesRequired 1
gptkbp:efficacyAgainstModerateToSevereCOVID19 66%
gptkbp:efficacyAgainstSevereCOVID19 85%
gptkbp:emergencyServices gptkb:United_States_Food_and_Drug_Administration
gptkbp:emergencyUseAuthorizationDate 2021-02-27
gptkbp:firstAdministered 2021
https://www.w3.org/2000/01/rdf-schema#label Johnson & Johnson COVID-19 vaccine
gptkbp:pregnancyCategory consult healthcare provider
gptkbp:rareAdverseEvent gptkb:Guillain-Barré_syndrome
thrombosis with thrombocytopenia syndrome
gptkbp:routeOfAdministration intramuscular injection
gptkbp:shelfLife 2 years at -20°C
3 months at 2–8°C
gptkbp:sideEffect fever
fatigue
headache
muscle pain
pain at injection site
gptkbp:storage 2–8°C
gptkbp:target gptkb:COVID-19
gptkbp:type viral vector vaccine
gptkbp:vectorFor gptkb:adenovirus_serotype_26_(Ad26)
gptkbp:website https://www.janssencovid19vaccine.com/
gptkbp:WHOEmergencyUseListing 2021-03-12
gptkbp:bfsParent gptkb:COVID-19
gptkb:COVID-19_pandemic
gptkbp:bfsLayer 4